Laser immunotherapy for treatment of patients with advanced breast cancer and melanoma

  title={Laser immunotherapy for treatment of patients with advanced breast cancer and melanoma},
  author={Xiaosong Li and Tomas Hode and Maria C. Guerra and Gabriela L. Ferrel and Robert E. Nordquist and Wei R. Chen},
  journal={Journal of Physics: Conference Series},
Laser immunotherapy (LIT) was developed for the treatment of metastatic tumors. It combines local selective photothermal interaction and active immunological stimulation to induce a long-term, systemic anti-tumor immunity. During the past sixteen years, LIT has been advanced from bench-top to bedside, with promising outcomes. In our pre-clinical and preliminary clinical studies, LIT has demonstrated the capability in inducing immunological responses, which not only can eradicate the treated… 

Mathematical models of the adaptive immune response in a novel cancer immunotherapy

Post-treatment immune dynamics with mathematical models are described, predictions of clinical treatment outcomes can be drawn from model predictions, and potential treatment designs that could be used to improve treatment outcome are indicated.



Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats.

Results revealed the important function of the immunoadjuvant in laser immunotherapy and significantly reduced the growth of primary tumors and lung metastases in rats bearing metastatic prostate tumors.

In situ photoimmunotherapy: a tumour‐directed treatment for melanoma

It is demonstrated that ISPI can clear local tumour and trigger beneficial systemic responses, with a side‐effect profile that compares favourably with other treatments for advanced melanoma.

Induced antitumor immunity against DMBA‐4 metastatic mammary tumors in rats using laser immunotherapy

The results show that laser immunotherapy could have potential for the treatment of metastatic tumors by inducing tumor‐specific, long‐lasting immunity and tumor regression and eradication and developed strong resistance to repeated challenges by tumor cells of the same type.

Enhancing cellular cancer vaccines.

Various types of cellular cancer vaccines are reviewed and a unique strategy designed to enrich cellular vaccines for cells that induce tumor immunity is described, in a mouse breast cancer model system.

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

This revision of the staging system for cutaneous melanoma will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.

Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual

The sixth edition of the AJCC Cancer Staging Manual contains some of the most extensive and significant revisions that have ever been made in the breast cancer staging system, reflecting recent clinical evidence or widespread clinical consensus.

Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway

It is shown that the imidazoquinolines activate immune cells via the Toll-like receptor 7 (TLR7)-MyD88–dependent signaling pathway, and that neither MyD88- nor TLR7-deficient mice showed any inflammatory cytokine production by macrophages, proliferation of splenocytes or maturation of dendritic cells.

Laser immunotherapy

In experiments using a rat metastatic tumor model, laser immunotherapy resulted in the eradication of both treated primary tumors and untreated metastases at remote sites and induced anti-tumor resistance.